title: MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study.
abstract: The contribution of melanocortin-1 receptor (MC1R) gene variants to the development of early-onset melanoma is unknown. Using an Australian population-based, case-control-family study, we sequenced MC1R for 565 cases with invasive cutaneous melanoma diagnosed between ages 18 and 39 years, 409 unrelated controls and 518 sibling controls. Variants were classified a priori into "R" variants (D84E, R142H, R151C, I155T, R160W, D294H) and "r" variants (all other nonsynonymous variants). We estimated odds ratios (OR) for melanoma using unconditional (unrelated controls) and conditional (sibling controls) logistic regression. The prevalence of having at least one R or r variant was 86% for cases, 73% for unrelated controls and 81% for sibling controls. R151C conferred the highest risk (per allele OR 2.57, 95% confidence interval 1.86-3.56 for the case-unrelated-control analysis and 1.70 (1.12-2.60) for the case-sibling-control analysis). When mutually adjusted, the ORs per R allele were 2.23 (1.77-2.80) and 2.06 (1.47-2.88), respectively, from the two types of analysis, and the ORs per r allele were 1.69 (1.33-2.13) and 1.25 (0.88-1.79), respectively. The associations were stronger for men and those with none or few nevi or with high childhood sun exposure. Adjustment for phenotype, nevi and sun exposure attenuated the overall log OR for R variants by approximately 18% but had lesser influence on r variant risk estimates. MC1R variants explained about 21% of the familial aggregation of melanoma. Some MC1R variants are important determinants of early-onset melanoma. The strength of association with melanoma differs according to the type and number of variants.
authors.affiliation: Cancer Epidemiology and Services Research, Sydney School of Public Health, The University of Sydney, Australia. anne.cust@sydney.edu.au
authors.forename: Anne E
authors.initials: AE
authors.lastname: Cust
authors.forename: Chris
authors.initials: C
authors.lastname: Goumas
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Holland
authors.forename: Chantelle
authors.initials: C
authors.lastname: Agha-Hamilton
authors.forename: Joanne F
authors.initials: JF
authors.lastname: Aitken
authors.forename: Bruce K
authors.initials: BK
authors.lastname: Armstrong
authors.forename: Graham G
authors.initials: GG
authors.lastname: Giles
authors.forename: Richard F
authors.initials: RF
authors.lastname: Kefford
authors.forename: Helen
authors.initials: H
authors.lastname: Schmid
authors.forename: John L
authors.initials: JL
authors.lastname: Hopper
authors.forename: Graham J
authors.initials: GJ
authors.lastname: Mann
authors.forename: Mark A
authors.initials: MA
authors.lastname: Jenkins
mesh_terms: D000293:Adolescent; D000328:Adult; D000483:Alleles; D001315:Australia; D001483:Base Sequence; D016022:Case-Control Studies; D005190:Family; D005260:Female; D005809:Genes, Regulator; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008543:Melanins / Q000096:biosynthesis; D008545:Melanoma / Q000453:epidemiology / Q000235:genetics*; D044102:Receptor, Melanocortin, Type 1 / Q000235:genetics*; D012306:Risk; D017422:Sequence Analysis, DNA; D012878:Skin Neoplasms / Q000453:epidemiology / Q000235:genetics*; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D008543:Melanins; D044102:Receptor, Melanocortin, Type 1
references.citation: Int J Cancer. 2008 Jun 15;122(12):2753-60
references.pmid: 18366057
references.citation: Hum Mol Genet. 2000 Oct 12;9(17):2531-7
references.pmid: 11030758
references.citation: Nat Genet. 2002 May;31(1):33-6
references.pmid: 11984562
references.citation: Cancer. 2010 May 15;116(10):2416-28
references.pmid: 20301115
references.citation: Hum Mol Genet. 2007 Sep 15;16(18):2249-60
references.pmid: 17616515
references.citation: Pigment Cell Res. 2005 Dec;18(6):393-410
references.pmid: 16280005
references.citation: Am J Epidemiol. 1999 Apr 15;149(8):693-705
references.pmid: 10206618
references.citation: Cancer Causes Control. 2010 Dec;21(12):2137-47
references.pmid: 20721616
references.citation: Ann Epidemiol. 2007 Sep;17(9):643-53
references.pmid: 17553702
references.citation: Hum Mol Genet. 1996 Oct;5(10):1663-6
references.pmid: 8894704
references.citation: Lancet. 2005 Oct 15-21;366(9494):1397-406
references.pmid: 16226618
references.citation: Ann Hum Genet. 1997 Jul;61(Pt 4):319-33
references.pmid: 9365785
references.citation: Oncogene. 2003 May 19;22(20):3053-62
references.pmid: 12789280
references.citation: BMC Genet. 2008 Apr 10;9:31
references.pmid: 18402696
references.citation: Int J Epidemiol. 2011 Oct;40(5):1342-54
references.pmid: 21771852
references.citation: J Invest Dermatol. 2001 Aug;117(2):294-300
references.pmid: 11511307
references.citation: Am J Hum Genet. 2000 Jan;66(1):176-86
references.pmid: 10631149
references.citation: Hum Mol Genet. 2004 Feb 15;13(4):447-61
references.pmid: 14709592
references.citation: Int J Epidemiol. 2006 Dec;35(6):1514-21
references.pmid: 16943234
references.citation: J Natl Cancer Inst Monogr. 1999;(26):31-7
references.pmid: 10854483
references.citation: Biochem Biophys Res Commun. 1999 Jul 5;260(2):488-91
references.pmid: 10403794
references.citation: Hum Mutat. 2007 May;28(5):495-505
references.pmid: 17279550
references.citation: Brief Bioinform. 2007 Nov;8(6):457-65
references.pmid: 17715151
references.citation: Am J Epidemiol. 2009 Dec 15;170(12):1541-54
references.pmid: 19887461
references.citation: Am J Hum Genet. 2000 Apr;66(4):1351-61
references.pmid: 10733465
references.citation: Cancer Res. 2006 Sep 15;66(18):9330-7
references.pmid: 16982779
references.citation: Int J Cancer. 2006 Oct 15;119(8):1976-84
references.pmid: 16721784
references.citation: Int J Cancer. 2011 Oct 1;129(7):1730-40
references.pmid: 21128237
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):808-19
references.pmid: 15159314